Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Change in Receivables (2017 - 2025)

Organogenesis Holdings (ORGO) has 10 years of Change in Receivables data on record, last reported at $51.5 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 484.71% year-over-year to $51.5 million; the TTM value through Dec 2025 reached $115.8 million, up 264.16%, while the annual FY2025 figure was $115.8 million, 264.16% up from the prior year.
  • Change in Receivables reached $51.5 million in Q4 2025 per ORGO's latest filing, up from $50.7 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $51.5 million in Q4 2025 and bottomed at -$7.3 million in Q4 2023.
  • Average Change in Receivables over 5 years is $9.0 million, with a median of $5.2 million recorded in 2021.
  • Peak YoY movement for Change in Receivables: tumbled 166.42% in 2023, then soared 1799.8% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $8.5 million in 2021, then tumbled by 132.21% to -$2.7 million in 2022, then crashed by 166.42% to -$7.3 million in 2023, then surged by 220.6% to $8.8 million in 2024, then surged by 484.71% to $51.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $51.5 million in Q4 2025, $50.7 million in Q3 2025, and $19.3 million in Q2 2025.